Dexamethasone-Induced Neutrophilia: Dose and Timing
Dexamethasone produces a significant neutrophil count increase at doses as low as 4–8 mg/m² (approximately 6–12 mg for an average adult), with the peak neutrophil rise occurring 4–6 hours after administration, followed by a second smaller rise at 24 hours. 1
Dose-Response Relationship
A single dose of 4 mg/m² dexamethasone (approximately 6 mg for an average adult) produces an adequate neutrophilia with minimal discomfort in healthy volunteers. 1
Higher doses produce greater neutrophil mobilization: When 8 mg oral dexamethasone is combined with G-CSF 600 mcg, the absolute neutrophil count increases from a baseline mean of 3,594/µL to 43,017/µL at 12 hours—representing a 12-fold increase. 2
Dexamethasone alone at 8 mg orally produces a dose-dependent neutrophil increase that is sustained for at least 24 hours. 3
Timing of Neutrophil Response
The maximum neutrophil count occurs 4–6 hours after either oral or intravenous administration of dexamethasone. 1
This initial peak is due almost entirely to an increase in mature neutrophils, not immature forms. 1
A second, smaller rise in neutrophil count occurs at 24 hours after oral administration. 1
When combined with G-CSF, the optimal timing for leukapheresis to harvest neutrophils is 12 hours after drug administration, as this achieves the greatest quantitative yield. 2
Mechanism and Clinical Implications
The neutrophilia represents demargination of mature neutrophils from the vascular endothelium rather than enhanced bone marrow production. 1
Concomitant with the neutrophil rise, there is a profound lymphocytopenia at 4 hours, followed by a rebound lymphocytosis at 24 hours. 1, 4
Monocyte counts decrease at 4 hours and rebound to supra-normal levels at 24 hours. 4
Eosinophil and basophil counts also decrease in a dose-dependent manner at 4 hours, with rebound increases at 24 hours. 3
Critical Clinical Caveat
Dexamethasone-induced leukocytosis does NOT reflect enhanced immune competence; instead, it signifies immunosuppression and an elevated risk of infections, particularly pneumonia. 5 This is a common pitfall—clinicians may misinterpret the elevated white blood cell count as indicating improved immune function, when in fact the opposite is true.
High-dose dexamethasone regimens are associated with approximately 16% incidence of pneumonia compared to 9% with low-dose therapy. 5
Grade ≥3 lymphopenia occurs in roughly 25–63% of patients receiving dexamethasone-containing regimens, underscoring the immunosuppressive effect despite the neutrophilia. 5
Functional Capacity of Recruited Neutrophils
Despite concerns about steroid effects on neutrophil function, the recruited neutrophils retain normal functional capabilities: viability (98.4%), phagocytic capacity (97.6%), fungicidal activity, bacterial killing (97.7%), and chemotaxis (119%) do not differ significantly from non-treated controls. 6
However, neutrophil alkaline phosphatase (NAP) activity falls as the neutrophil count rises during dexamethasone administration. 1
Plasma Concentration Correlation
There is a direct relationship between plasma concentration of dexamethasone and the rise in neutrophil count following intravenous (but not oral) administration. 1
The plasma concentration of dexamethasone falls to half its peak value in 2–6 hours. 1